ArticleCureus2025
Four-Year Experience With the ALTO Stent Graft in Abdominal Aortic Aneurysms With Hostile Features.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Re-intervention for type III endoleak after endovascular aneurysm repair with an ALTO stent graft: a case description.Quantitative imaging in medicine and surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLow-profile stent grafts with polymer ring sealing technology expanded the use of endovascular aortic repair (EVAR) to include short conical necks and small access vessels in general. We examined the use of the ALTO stent graft (Endologix LLC, Irvine, CA) in our regional vascular centre to assess its real-life performance in cases deemed not suitable for standard stenting. This was an independent, single-centre study with no financial or material involvement from the device manufacturer.
methodsThis was a retrospective observational review of all consecutive patients treated with the ALTO stent graft between May 2020 and June 2024. Patient demographics, anatomical and radiological features, re-interventions, and general follow-up data were collected. Primary endpoints included long-term survival and freedom from Type Ia endoleak. Secondary outcomes included sac expansion and reinterventions. Results: Forty-nine patients were included, of whom 71.4% were not fit for open repair. Median follow-up was 48 months. Half of the patients had a flared/conical neck, 20% had significant neck thrombus, and 30% had a small aortic bifurcation or small iliac vessels. The median length of the conical/flared neck was 10.5 mm (4-48 mm). Median maximal aortic neck diameter was 25.5 mm (19.5-31 mm). Median iliac artery diameter was 6.5 mm (4-9 mm). The technical success rate was 98%, with only one patient converted to open. One patient died within 30 days after discharge from chronic obstructive pulmonary disease (COPD)/COVID. Freedom from reintervention at 12, 24, 36, and 48 months was 100%, 100%, 100%, and 85.71%, respectively. One patient developed a Type III endoleak after four years. We observed no aneurysm-related mortality. Conclusion: The ALTO stent-graft system demonstrates an effective and durable seal in abdominal aortic aneurysm (AAA) cases with hostile features, with outcomes comparable to standard EVAR, expanding the options for patients less fit for open repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.